Evidence map›Paper›PMID 35955795›Full record

ReviewInternational journal of molecular sciences2022

Engineering Hyaluronic Acid for the Development of New Treatment Strategies for Osteoarthritis.

Yu Seon Kim, Farshid Guilak

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 48 citations in OpenAlex.

  1. The Role of ButirprostMedicina (Kaunas, Lithuania) · 2025
    Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. (Chemical) Roles of HOCl in Rheumatic Diseases.Antioxidants (Basel, Switzerland) · 2024
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Yu Seon KimDepartment of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
Farshid GuilakDepartment of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0001-7380-0330
Washington University in St. Louis · US

Funding

VISCOELASTIC PROPERTIES OF NORMAL AND OA CHONDRONSR01AG015768 · NIA · WASHINGTON UNIVERSITY · PI GUILAK, FARSHID · 1998 to 2022
$7.7M
Washington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Alfred Hyoungju Kim · 2018 to 2026
$7.6M
Resource Based Center for Musculoskeletal Biology and Medicine (Overall Application)P30AR074992 · NIAMS · WASHINGTON UNIVERSITY · PI MATTHEW J SILVA · 2019 to 2026
$6.8M
Genetically-engineered stem cells for self-regulating arthritis therapyR01AR080902 · NIAMS · WASHINGTON UNIVERSITY · PI Farshid Guilak, Christine T. Pham · 2022 to 2026
$3.7M
OBESITY, BIOMECHANICS, AND INFLAMMATION IN OSTEOARTHRITISR01AG046927 · NIA · WASHINGTON UNIVERSITY · PI GUILAK, FARSHID · 2013 to 2023
$3.2M
Deconstructing Cartilage Mechanotransduction by Piezo ChannelsR01AR072999 · NIAMS · WASHINGTON UNIVERSITY · PI GUILAK, FARSHID · 2020 to 2024
$2.9M
NIAMS NIH HHS P30 AR073752NIAMS NIH HHS P30 AR074992NIAMS NIH HHS R01 AR072999NIAMS NIH HHS R01 AR080902NIA NIH HHS R01 AG015768NIA NIH HHS R01 AG046927NIH HHS AG15768
6 · The paper itself

Abstract

Osteoarthritis (OA) is a degenerative joint disease that is characterized by inflammation of the joints, degradation of cartilage, and the remodeling of other joint tissues. Due to the absence of disease-modifying drugs for OA, current clinical treatment options are often only effective at slowing down disease progression and focus mainly on pain management. The field of tissue engineering has therefore been focusing on developing strategies that could be used not only to alleviate symptoms of OA but also to regenerate the damaged tissue. Hyaluronic acid (HA), an integral component of both the synovial fluid and articular cartilage, has gained widespread usage in developing hydrogels that deliver cells and biomolecules to the OA joint thanks to its biocompatibility and ability to support cell growth and the chondrogenic differentiation of encapsulated stem cells, providing binding sites for growth factors. Tissue-engineering strategies have further attempted to improve the role of HA as an OA therapeutic by developing diverse modified HA delivery platforms for enhanced joint retention and controlled drug release. This review summarizes recent advances in developing HA-based hydrogels for OA treatment and provides additional insights into how HA-based therapeutics could be further improved to maximize their potential as a viable treatment option for OA.

Indexed as

Cartilage, ArticularOsteoarthritisHumansHyaluronic AcidHydrogelsSynovial FluidHyaluronic AcidHydrogelsaggrecanarthritisproteoglycanregenerative medicine

Identifiers

PMID35955795
PMCPMC9369020
OpenAlexW4289833815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.